

flucloxacillin

500mg injection, oral mixture

© Department of Health, Government of South Australia. All rights reserved

Note

This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient's medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Synonyms

Floxacin

ISBN number:
Endorsed by:
Last Revised:
Contact:

978-1-74243-395-0
South Australian Maternal & Neonatal Clinical Network
06/11/2012
South Australian Neonatal Medication Guidelines Workgroup at:
NeoMed@health.sa.gov.au

flucloxacillin

500mg injection, oral mixture

Dose and Indications**Infection Due To Susceptible Gram Positive Organisms****Intravenous, Intramuscular**

50mg/kg/dose

Corrected Age (weeks) [Gestational Age PLUS Postnatal Age]	Postnatal age (days)	Frequency (hours)
All (up to 44 weeks)	≤ 7	every 12 hours
	7 to 28	every 8 hours
	≥28	every 6 hours

Length of treatment should be guided by pathology and clinical picture; however in proven sepsis treatment should continue for a minimum of 7 days.

Oral

25mg/kg/dose

Corrected Age (weeks) [Gestational Age PLUS Postnatal Age]	Postnatal age (days)	Frequency (hours)
All (up to 44 weeks)	≤ 7	every 12 hours
	7 to 28	every 8 hours
	≥28	every 6 hours

Length of treatment should be guided by pathology and clinical picture; however in proven sepsis treatment should continue for a minimum of 7 days.

Staphylococcal Osteomyelitis, Meningitis or Cerebral Abscess**Intravenous, Intramuscular**

100mg/kg/dose

Corrected Age (weeks) [Gestational Age PLUS Postnatal Age]	Postnatal age (days)	Frequency (hours)
All (up to 44 weeks)	≤ 7	every 12 hours
	7 to 28	every 8 hours
	≥28	every 6 hours

Length of treatment should be guided by pathology and clinical picture; however in proven sepsis treatment should continue for a minimum of 21 days.

ISBN number:
Endorsed by:
Last Revised:
Contact:

978-1-74243-395-0
South Australian Maternal & Neonatal Clinical Network
06/11/2012
South Australian Neonatal Medication Guidelines Workgroup at:
NeoMed@health.sa.gov.au

flucloxacillin

500mg injection, oral mixture

Preparation and Administration

Intravenous

Vial Strength (mg)	Volume of Water for Injection (WFI) to add (mL)	Final Concentration of flucloxacillin (mg/mL)
500mg	9.6mL	50mg/mL

Dose	25mg	50mg	75mg	100mg	125mg	150mg
Volume	0.5mL	1mL	1.5mL	2mL	2.5mL	3mL

Administer as an infusion over at least 30 minutes

The reconstituted solution is stable for 24 hours stored under refrigeration – check with local policy about re-accessing vial for the same patient.

Intramuscular

Vial Strength (mg)	Volume of WFI to add (mL)	Final Concentration of flucloxacillin (mg/mL)
500mg	1.6mL	250mg/mL

Dose	25mg	50mg	75mg	100mg	125mg	150mg
Volume	0.1mL	0.2mL	0.3mL	0.4mL	0.5mL	0.6mL

The reconstituted solution is stable for 24 hours stored under refrigeration – check with local policy about re-accessing vial for the same patient.

Oral

There are various strengths available, refer to local guidelines for the specific strength available at your institution or unit and product information for reconstitution volume.

The reconstituted solution is usually stable for 7 days stored under refrigeration; however this may change according to brand available. Please consult product information.

Oral doses should be given on an empty stomach, where possible.

Compatible Fluids

Glucose 5%, sodium chloride 0.9%

ISBN number:
Endorsed by:
Last Revised:
Contact:

978-1-74243-395-0
South Australian Maternal & Neonatal Clinical Network
06/11/2012
South Australian Neonatal Medication Guidelines Workgroup at:
NeoMed@health.sa.gov.au

flucloxacillin

500mg injection, oral mixture

Adverse Effects**Common**

Diarrhoea, pain and inflammation at injection site, transient increases in liver enzymes and bilirubin

Infrequent

Vomiting, [Clostridium difficile -associated disease](#)

Rare

Black tongue, electrolyte disturbances, neurotoxicity, bleeding, blood dyscrasias, hepatic reactions, including severe cholestatic hepatitis (especially in treatment >2 weeks).

Anaphylactic shock is not commonly seen in the neonates

Monitoring

- > Observe intravenous site for extravasations
- > Periodic liver function tests on long term therapy.
- > Practice Points
- > There have been reports of severe, delayed cholestatic jaundice in adults particularly after treatment for more than 2 weeks. While this has not been recognised with neonatal use, caution would be recommended in this population.

Version control and change history

PDS reference: OCE use only

Version	Date from	Date to	Amendment
1.0	November 2012	current	Original version

ISBN number:
Endorsed by:
Last Revised:
Contact:

978-1-74243-395-0
 South Australian Maternal & Neonatal Clinical Network
 06/11/2012
 South Australian Neonatal Medication Guidelines Workgroup at:
 NeoMed@health.sa.gov.au